智飞生物改良型安卡拉痘苗病毒（MVA）猴痘减毒活疫苗临床试验申请获受理

Core Viewpoint - The company Zhifei Biological Products (智飞生物) announced that its subsidiary, Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd. (智飞龙科马), has received a clinical trial application acceptance notice from the National Medical Products Administration for its modified Ankara strain monkeypox live attenuated vaccine [1] Group 1 - The modified Ankara strain monkeypox live attenuated vaccine is developed to prevent monkeypox disease caused by the monkeypox virus [1] - The vaccine is intended for use in individuals aged 6 years and older [1] - The company can commence clinical trials within 60 days if no negative or questioning opinions are received from the drug review center after the acceptance of the application [1]